問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Division of Thoracic Medicine

E-DA Hospital (在職)

更新時間：2023-09-19

周柏安
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周柏安

List

29Cases

2025-10-01 - 2028-12-31

Active
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Injectable frozen powder

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2040-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-12-30 - 2024-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

Terminated2Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-01-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-09-15 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2022-04-01 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2022-12-01 - 2026-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2020-05-01 - 2024-04-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2021-01-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB